Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Pharmacokinetics and Gonadotropin Suppression of Nestorone®-Testosterone (NES/T) Combination Gel in Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male volunteers in good health as confirmed by physical examination, medical history, and clinical laboratory tests of blood and urine at the time of screening;~2. 18 to 50 years of age;~3. BMI \< 33 calculated as weight in Kg/(height in cm)2;~4. No history of hormonal therapy use in the last six months prior to the first screening visit;~5. Subject will agree to use a recognized effective method of contraception with his partner (i.e. at a minimum, condom for the male partner and an effective contraception for the female partner) during the course of the study treatment and recovery phase;~6. In the opinion of the investigator, subject is able to comply with the protocol, understand and sign an informed consent and HIPAA form;~7. Does not meet any of the exclusion criteria.~8. Sperm concentration ≥ 15 million sperm per milliliter ejaculate.~Exclusion Criteria:~1. Men participating in another clinical trial involving an investigational drug within the last 30 days prior to the first screening visit;~2. Men not living in the catchment's area of the clinic or within a reasonable distance from the site;~3. Clinically significant abnormal physical findings at screening;~4. Elevated PSA (levels ≥ 4 ng/mL), according to local laboratory normal values;~5. Abnormal serum chemistry values, according to local laboratory normal values that indicate liver or kidney dysfunction or that may be considered clinically significant;~6. Use of androgens or body building substances within 6 months before first screening visit;~7. Diastolic blood pressure (DBP) \> 80 and/or Systolic (SBP) \> 130 mm Hg;~8. EKG abnormal and clinically significant and QTC level longer than 450msec;~9. History of hypertension, including hypertension controlled with treatment;~10. Known history of primary testicular disease or disorders of the hypothalamic-pituitary axis;~11. Known hypersensitivity to progestins or androgen;~12. Family or personal history of venous thromboembolism;~13. Benign or malignant liver tumors; active liver disease;~14. Known history of reproductive dysfunction including vasectomy or infertility;~15. Known history of cardiovascular, renal, hepatic or prostatic disease;~16. A serious systemic disease such as diabetes mellitus or morbid obesity (body weight greater than 120% of ideal body weight or BMI limitation as above);~17. Known or suspected alcoholism or drug abuse that may affect metabolism/transformation of steroid hormones and study treatment compliance;~18. Known dermatitis or severe skin disorder;~19. Moderate or severe depression as determined by PHQ-9 score \>15;~20. Partner is known to be pregnant;~21. Known or suspected breast or prostate cancer;~22. Allergic to any ingredient in testosterone/nestorone gel, including alcohol;~23. Known history of untreated sleep apnea;~24. International Prostate Symptom Score (IPSS) greater than or equal to 15.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): 5.0 mL of the 1.62% Nestorone® /testosterone gel (containing 8.3 mg NES + 62.5 mg T) applied each day on the arms and shoulders
- Group 2 (Type: EXPERIMENTAL): 4.4 mL of the 1.62% Testosterone only gel (AndrogelTM) (containing 62.7 mg T) applied each day to the arms and shoulders

Based on this trial design, predict the completion outcome and termination type (if applicable).